Erasca Financial Ratios
NASDAQ: ERASHealth CareBiotechnology: Pharmaceutical PreparationsUSD
16.03+0.57 (+3.69%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Erasca ratio analysis
Return on equity reached -38.3%, meaning Erasca generated -0.38 dollars of profit for every dollar of shareholders' equity. Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.
Summary generated from market data by MetaCap's automated system. Methodology
Erasca financial ratios (annual)
| Ratio | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Price / book | 3.13 | 1.51 | 1.01 | 1.28 | 2.26 | — |
| Return on equity (ROE) | -38.3% | -38.2% | -39.5% | -59.0% | -26.9% | — |
| Return on assets (ROA) | -31.4% | -32.2% | -31.6% | -47.2% | -24.5% | -81.4% |
| Current ratio | 10.04 | 9.84 | 12.26 | 9.13 | 16.02 | 8.77 |